OrthoPediatrics (KIDS) Q1 2026 earnings review
Operating Leverage Takes Center Stage as Profitability Accelerates
OrthoPediatrics delivered a disciplined Q1, proving its transition from a cash-burning growth story to a self-funding enterprise is on track. Revenue grew a stable 13% to $59.4M, but the real highlight was the bottom line. Management successfully decoupled expense growth from revenue growth—total operating expenses rose just 5%. This dramatic operating leverage pushed Adjusted EBITDA to $2.2M (up from a loss of $0.4M a year ago) and reduced Q1 free cash flow usage by 40%. Full-year revenue guidance was nudged higher, and the path to 2026 free cash flow breakeven looks increasingly credible.
🐂 Bull Case
The company is finally exhibiting significant operating leverage. With OpEx growing at less than half the pace of revenue, Adjusted EBITDA is accelerating. The $25M FY26 EBITDA target is highly achievable.
Both domestic (+11%) and international (+22%) segments posted solid double-digit growth, driven by a multi-year super cycle of new products like VerteGlide and the OPSB clinic expansion.
🐻 Bear Case
The days of 20%+ top-line growth appear to be over. Core segments like Scoliosis are decelerating from the mid-30s growth rates seen in early 2025 down to 13%.
R&D spending actually declined 5% YoY in Q1. While management attributes this to timing, chronically underfunding R&D to hit near-term profitability targets could jeopardize future product cycles.
⚖️ Verdict: 🟢
Bullish. The top-line growth is stable, but the bottom-line improvement is exceptional. Management is delivering exactly what they promised: a clear, execution-driven path to free cash flow breakeven.
Key Themes
Dramatic Operating Leverage Realized
The most important takeaway from Q1 is the strict cost control. While revenue grew 13%, General & Administrative expenses grew just 2%, and R&D fell 5%. Sales & Marketing grew 11%, closely tracking volume. This accelerating operating leverage is the primary driver bridging the company from a $14.8M Adjusted EBITDA in FY25 to the targeted $25.0M in FY26.
International Business Reversing Course
International revenue surged 22% YoY to $14.1M, a reversing trend from the sluggish 6-12% growth rates seen in mid-2025 that were plagued by Latin American stocking headwinds. Recent EU MDR approvals are acting as a major catalyst, finally allowing the company to deploy its full product portfolio across European markets.
Scoliosis Segment Decelerating
Scoliosis revenue grew 13% YoY to $15.4M. While healthy, this marks a severe decelerating trend compared to the 34% and 35% growth rates posted in Q1 and Q2 of 2025. The normalization suggests that the initial massive adoption surge of the ApiFix and RESPONSE systems may be plateauing, making future market share gains harder fought.
Declining R&D Investment
R&D expenses fell 5% YoY to $2.2M in Q1. This metric was previously flagged as a concern during the 2025 Q4 earnings call when full-year R&D spending also dropped. Management has consistently blamed the 'timing of product development third-party invoices,' but two consecutive periods of R&D contraction for a medical device company reliant on a 'multi-year super cycle' of new products warrants close monitoring.
OPSB (Specialty Bracing) Continues to Scale
The OrthoPediatrics Specialty Bracing (OPSB) division remains a critical, capital-efficient growth engine. Management noted that scaling OPSB through new products and clinic expansion significantly supported the 14% growth in the broader Trauma & Deformity segment. Because OPSB carries a lower Sales & Marketing expense profile than surgical implants, its outsized growth directly fuels the company's margin expansion.
Other KPIs
Grew 14% YoY, driven by strong adoption of Pega products, Ex-Fix, and OPSB. This segment remains the bedrock of the company, accounting for 72% of total revenue.
A 40% improvement compared to the $8.4M used in Q1 2025. Q1 is historically the company's weakest cash flow quarter due to seasonality, making this massive YoY reduction a strong indicator that full-year breakeven is achievable.
Stable YoY. Gross margins have consistently hovered in the 72-74% range, indicating that premium pricing on new products is successfully offsetting any inflationary manufacturing pressures or lower-margin international set sales.
Guidance
Stable. The company raised the bottom end of its previous $262.0 - $266.0M guidance. The new range implies 11% to 13% YoY growth, maintaining a consistent, low-teens top-line trajectory.
Accelerating. Reiterated guidance represents a massive ~69% jump from the $14.8M generated in FY25. Achieving this requires the strict operating expense control demonstrated in Q1 to continue through the year.
Accelerating. Up from a $15.0M burn in FY25 and a $42.0M burn in FY24. This is the ultimate financial milestone for the company, effectively ending its reliance on external capital to fund operations.
Key Questions
7D Capital Equipment Placements
In late 2025, management cited slower-than-expected hospital paperwork processing for 7D capital sales. Did 7D placement volumes normalize in Q1, or are capital equipment budgets remaining tight?
R&D Spending Trajectory
R&D spend has declined YoY. At what point in 2026 should investors expect R&D expenditures to ramp back up to support the next wave of the 'multi-year super cycle'?
Latin America Stocking Headwinds
International revenue rebounded strongly this quarter. Does this 22% growth indicate that the distributor destocking issues in Brazil and the broader Latin American market have been fully resolved?